Efficacy of a new COVID-19 treatment
Phase 2
- Conditions
- COVID-19
- Registration Number
- PACTR202006899597082
- Lead Sponsor
- Malagasy government
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Adults aged between 18 to 70
• COVID-19 confirmed by a RT-PCR test in real time 4 days before being enrolled in the clinical trial
• Patients with moderate signs of COVID-19
• Patients consenting voluntarily and freely
Exclusion Criteria
Contraindications to the drug tested
• Patients who require breathing apparatus (eg invasive ventilation, invasive mechanical ventilation, oxygenation of the extra-corporeal membrane)
• Patients who participated in other clinical trials related to COVID-19
• Patients who received medication directly treating COVID-19 24 hours before the start of the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method